Boswellia (Frankincense).
May offer mild joint support and comfort. Helps soothe stiff, achy joints. The active compounds (boswellic acids) seem to dial down some inflammatory pathways in the body.
Reviewed March 2026
- Category
- Herb
- Also filed under
- Joint HealthInflammation Support
What Boswellia (Frankincense) is, and what it does.
- Does it work
- Maybe. The evidence is decent, but not a slam dunk like curcumin or fish oil. A good 'plan B' for joint support.
- How much to take
- Start with 100 to 300mg a day of an extract standardised to its boswellic acids, with a meal containing fat, since those acids dissolve in fat rather than water.
- Time to feel it
- As early as five days of daily use.
- The first dose
- Nothing. This isn't ibuprofen. You need to give it a month, at least.
- With regular use
- After 4-8 weeks, some people report less morning stiffness and better mobility. The effects are typically mild but consistent.
- How well tolerated
- Generally well tolerated. The main issue is a potential interaction with blood thinners. Some people get mild stomach upset, but it's rare.
- How it feels
- Like a slow-acting joint soother. You don't feel it 'kick in.' You just might notice less background noise from your joints over time.
- The overlooked benefit
- It blocks 5-lipoxygenase, a different enzyme family from the one most joint products act on, so it adds a second angle instead of doubling up on the same pathway.
100 to 300mg a day is where Boswellia (Frankincense) works.
Source: Yu 2020 OA meta + Siddiqui 2011 review
In a 30 day randomised, double blind, placebo controlled trial, 70 adults with knee osteoarthritis took 100 mg a day of a branded Boswellia serrata extract standardised to 20 percent acetyl-11-keto-beta-boswellic acid, or placebo, with pain and function scored at day 0, day 5 and day 30. Pain scores improved by day 5 and continued to day 30, and circulating MMP-3, TNF alpha and high sensitivity C reactive protein fell. A separate 120 day trial in 48 adults, run by staff of the extract manufacturer, recorded reduced pain and stiffness and lower high sensitivity C reactive protein over the longer period.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Research suggests Boswellia may have anti-inflammatory properties that can support joint health. However, the evidence is not as strong or consistent as some other joint health supplements.
- Joint comfort and stiffnessMeta-analysis
- Joint mobility and walking distanceRandomised trial
- Inflammatory enzyme activityIn vitro study
- Digestive comfortRandomised trial
- Breathing comfortRandomised trial
- Cartilage matrix breakdown markersAnimal study
Questions people ask about Boswellia (Frankincense).
- How is this different from turmeric or curcumin?
- They work on different inflammatory pathways. Boswellia targets 5-LOX, while curcumin hits COX-2. Some people stack them.
- How long until I know if it's working?
- Give it at least 4-8 weeks of consistent daily use. If you feel nothing by then, it might not be for you.
- Can I take it with ibuprofen or other NSAIDs?
- Generally yes, but check with your doctor. They work differently, but it's always good to be cautious when mixing things for inflammation.
- Does the supplement smell like frankincense incense?
- Usually not. The extraction process that concentrates the active compounds removes most of the aromatic oils.
- What does 'standardized extract' mean?
- It means the manufacturer guarantees a specific amount of the active ingredient, like boswellic acids or AKBA. It's a quality marker.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Boswellic acids specifically inhibit 5-lipoxygenase, the enzyme that converts arachidonic acid into leukotrienes, while curcumin works more broadly across cyclooxygenase and NF-kB signaling. Covering these two separate arms of the body's normal inflammatory-response signaling is the long-standing reason the two extracts are formulated together in joint-comfort blends.
EPA displaces arachidonic acid from membrane phospholipids so less substrate enters the leukotriene route, while boswellic acids act on the 5-lipoxygenase enzyme itself. Substrate and enzyme are two different points on one pathway.
Bromelain acts proteolytically on kinin and prostaglandin signalling, separate from the lipoxygenase step boswellic acids occupy.
Gingerols act on the cyclooxygenase branch while boswellic acids act on the leukotriene branch of arachidonate metabolism. Together they cover both outputs of the same substrate.
Boswellic acids are lipophilic and absorb several times better when the dose arrives with fat. A lipid carrier substitutes for taking the capsule with a fatty meal.
Piperine slows glucuronidation and intestinal efflux transport, the two routes that keep systemic boswellic acid exposure low.
Glucosamine feeds glycosaminoglycan synthesis in cartilage while frankincense resin acids act on eicosanoid signalling around it.
Chondroitin is a structural glycosaminoglycan and also damps matrix-degrading enzyme activity, a role boswellia does not fill.
MSM supplies sulfur for glycosaminoglycan sulfation and glutathione synthesis in connective tissue. Boswellia contributes nothing to sulfur supply.
Quercetin damps lipoxygenase activity and mediator release from mast cells, overlapping the enzyme step boswellic acids act on. The result is additive rather than independent.
Salicin becomes salicylate, which acts on cyclooxygenase and on normal platelet aggregation. Layered on boswellia and fish oil, the effect on normal clotting is additive.
Frankincense extract has been formulated together with curcumin and vitamin C in a multi-ingredient product taken into a phase II clinical study. What was tested was the whole product, so no statement about frankincense alone follows from it. The row records the co-formulation, not an effect.
Boswellic acids are lipophilic pentacyclic triterpenes with poor aqueous solubility, and complexing them with phospholipid is the standard formulation answer for that class of molecule. The lecithin complex is designed to improve dispersion in the gut rather than to add its own activity. This is formulation practice.
Phosphatidylcholine is the specific phospholipid used to build triterpene phytosome complexes, where the polar head associates with the acid group and the acyl chains face outward. The complex disperses more readily in intestinal fluid than the raw resin extract. Comparative human absorption data across delivery systems is limited, so the rationale stays a delivery one.
Boswellia extract and collagen peptides appear together in joint comfort formulas because they act on different things: one on eicosanoid signalling, the other supplying amino acids for connective tissue matrix. Each has its own separate literature and the combination has little joint testing. The pairing is formulation convention.
Hyaluronic acid contributes to the viscosity of synovial fluid and to tissue hydration, which is a different lever from the enzyme-level actions attributed to boswellic acids. Products combine them to cover both aspects of joint comfort and mobility during activity. The combination itself is not well studied.
Boswellia and ashwagandha are long-standing partners in Ayurvedic joint preparations and continue to appear together in modern formulas. The traditional pairing carries ethnobotanical weight and modern combination data is thin. Each ingredient's own evidence is where the substance lies.
Frankincense has been used as a substrate in a laboratory synbiotic beverage development study, where it was fermented alongside a live culture. That is food science characterisation rather than a human finding. It supports the idea that the resin material can carry a fermentation, nothing beyond that.
Boswellic acids and catechins are both described as acting on lipoxygenase-derived mediators and on NF-kB dependent transcription in laboratory systems. That overlap is the reason they appear in the same formulas. The evidence sits at the cell and enzyme level and combined human data is absent.
Talk to a doctor before taking Boswellia (Frankincense) if any of these apply to you: Pregnancy, Breastfeeding, Blood Thinners. These are flags to check first, not effects Boswellia (Frankincense) is known to cause.
Not medical advice. Show the label to your pharmacist.What Boswellia (Frankincense) actually does.
The active compounds are the boswellic acids in the tree resin, with AKBA the one extracts are usually standardised on.
It slows one specific enzyme in the inflammatory signalling chain, and it does so at a different spot on that enzyme than most compounds use.
There is not much AKBA in raw resin, so extracts concentrate it and the label usually states how much.
These compounds do not dissolve well in water, so taking them with food that contains fat helps absorption.
Where Boswellia (Frankincense) comes from.
Workers cut the bark of the tree and collect the hardened resin that seeps out. That resin is cleaned, milled and washed with a solvent to pull out the active acids, which are then dried, tested and either sold as powder or bound to a phospholipid to help them disperse.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
The bark of Boswellia serrata, carterii or papyrifera is incised and the exuded resin is allowed to harden on the trunk before it is collected by hand. Yield and composition depend on species, season and how often a tree is tapped, and over-tapping damages the tree, which is why sourcing provenance is a real specification.
Collected tears are graded by size and colour, cleaned of bark, dried and milled. The essential oil fraction is partly lost at this stage depending on how much heat is used.
The milled resin is extracted, commonly with ethanol, ethyl acetate or a hydrocarbon solvent, which pulls the boswellic acids away from the water-soluble gum polysaccharides.
The extract is concentrated under vacuum and the residual gum fraction removed. Residual solvent becomes a specification to test on the finished powder.
The concentrate is assayed by HPLC and blended to a declared percentage of total boswellic acids, and separately for AKBA where the label claims it. Enriched grades take an extra separation step.
The standardised extract is dried, sometimes onto a carrier for flow, or complexed with phosphatidylcholine to make a phytosome grade.
Labels often say boswellia without naming the species, and they rarely state the extraction solvent or the tapping origin, both of which change what is in the powder.
The forms it comes in.
The essence, in one line each.
- Across 39 randomised trials in 4,599 adults with ongoing knee joint discomfort, Boswellia improved WOMAC pain by about 10.6 points, stiffness by about 9.5 points and joint function by about 14.0 points versus placebo, and ranked first of seven supplements for pain and stiffness.Meta-analysis. Zhang et al., 2025 (Nutrients). PMID 40806131 ↗
- Pooling 7 randomised trials in 545 adults, Boswellia and its extracts lowered pain on a 100 point visual analogue scale by about 8.3 points and improved joint stiffness and function scores, with a suggested minimum of 4 weeks of use.Meta-analysis. Yu et al., 2020 (BMC Complementary Medicine and Therapies). PMID 32680575 ↗
- Across 11 randomised trials in 1,009 people, Boswellia formulations were more effective than placebo for knee joint pain and physical function with no increase in side effects, though the authors judged the studies small and of low quality.Meta-analysis. Bannuru et al., 2018 (Seminars in Arthritis and Rheumatism). PMID 29622343 ↗
- In 13 studies covering 850 adults for WOMAC and 1,185 for the pain scale, the overall pooled analysis did not detect a difference from control because the trials varied so much, while the placebo-controlled subgroup did show lower WOMAC joint scores with Boswellia.Meta-analysis. Dalmonte et al., 2024 (Phytotherapy Research). PMID 39314013 ↗
- Pooling trials in adults with elevated blood sugar, boswellia supplementation was linked with lower fasting blood sugar and total cholesterol readings, across a small number of modest-sized studies.Systematic review. Karimi et al., 2024 (Frontiers in clinical diabetes and healthcare). PMID 39449720 ↗
- A standardised Boswellia serrata extract improved reported knee joint function scores and imaging measures of cartilage over the trial compared with placebo.Randomised trial. Kumar et al., 2025 (Journal of the American Nutrition Association). PMID 39700461 ↗
- Boswellia serrata extract, on its own or paired with an omega-3 product, improved reported knee pain and physical function versus placebo.Randomised trial. Pérez-Piñero et al., 2023 (Nutrients). PMID 37686880 ↗
- In adults with sudden loose stools, a lecithin-delivered boswellia extract shortened the time to normal stool form compared with control.Randomised trial. Giacosa et al., 2022 (Nutrients). PMID 35565826 ↗
- In a small placebo-controlled pilot, a boswellia preparation improved reported joint pain and function scores and was tolerated without notable changes in blood safety markers.Randomised trial. Majeed et al., 2019 (Phytotherapy research : PTR). PMID 30838706 ↗
- Curcumin combined with boswellic acid improved reported knee pain and walking measures more than curcumin alone over 12 weeks in adults with joint discomfort.Randomised trial. Haroyan et al., 2018 (BMC complementary and alternative medicine). PMID 29316908 ↗
- Supplementing milk replacer with Boswellia serrata resin was assessed for growth performance and serum measures in young calves; a livestock feeding study reporting production and blood parameters.Animal study. Abu Aziz B et al., 2026 (Animals). PMID 41751087 ↗
- Evaluates performance measures and gene expression in two strains of Japanese quail supplemented with frankincense; the endpoints are growth performance and tissue expression markers in birds.Animal study. Elkhoriby EE et al., 2026 (Scientific Reports). PMID 42248899 ↗
- Develops and characterises fermented functional beverages built from frankincense and Pistacia atlantica as a synbiotic substrate, reporting fermentation and product characteristics in the laboratory.In vitro study. Alhelfi N et al., 2025 (Food Science and Nutrition). PMID 41200211 ↗
- Describes a standardised combination of Boswellia serrata and Terminalia chebula extracts; boswellia is named within a report on the combined preparation rather than assessed on its own.Narrative review. Salter D et al., 2025 (Frontiers in Nutrition). PMID 41438191 ↗
- A phase II prospective study of ArtemiC, a multi-ingredient preparation containing frankincense alongside artemisinin, curcumin and vitamin C, given to hospitalised adults with a respiratory infection; the product was tested as a whole and boswellia's own contribution cannot be read from it.Randomised trial. Hellou E et al., 2022 (Journal of Cellular and Molecular Medicine). PMID 35587574 ↗
These are the studies our verdict leans on, chosen from the 1,168 we read for Boswellia (Frankincense). The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.